Prescribing Trends for Novel Treatments in Systemic Lupus from 2017 to 2022 (ACR Convergence 2024) - Sep 25, 2024 - Abstract #1549; Pres time: Nov 17, 2024; 10:30 AM - 12:30 PM; Location: Hall C; In Person; "Belimumab, anifrolumab and voclosporin exhibited an increase in claims from 2017-2022, with belimumab having a nearly 600% increase over the time-period, reflecting increased physician uptake of these medications. Our data suggests that Southern states have greater prescription rates of these medications, which, among other factors, may reflect regional variations in SLE prevalence. Interestingly, all claims for anifrolumab in 2021 came from the West, which may reflect factors such as different rates of marketing, information dissemination, etc."
Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Rheumatology • Systemic Lupus Erythematosus
|
|
Celestine He1; Zhonghan Li1; Sumanth Chennareddy2; Chrisanna Dobrowolski3
|